NasdaqGM - Nasdaq Real Time Price USD

Vericel Corporation (VCEL)

44.89 -1.22 (-2.64%)
As of 11:52 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Dominick C. Colangelo Esq. CEO, President & Director 1.54M 1.51M 1964
Mr. Joseph Anthony Mara Jr. CFO & Treasurer 750.61k -- 1976
Mr. Michael Halpin Chief Operating Officer 796.91k 492.26k 1962
Mr. Sean C. Flynn Chief Legal Officer 657.01k -- 1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer 672.16k 127.25k 1962
Mr. Jonathan D. Siegal Principal Accounting Officer, VP & Corporate Controller -- -- --
Mr. Eric Burns Vice President of Finance & Investor Relations -- -- --
Mr. Patrick J. Fowler Senior Vice President of Corporate Development & Strategy -- -- --
Mr. Patrick Helfrich Vice President of Marketing & Commercial Strategy -- -- --
Mr. Mike Gilligan Senior Vice President of Sales -- -- --

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States
617 588 5555 https://vcel.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
314

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Vericel Corporation’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024
Vericel Corporation Earnings Call

Related Tickers

MDWD MediWound Ltd.
18.16
+3.25%
 
APGE Apogee Therapeutics, Inc.
46.23
-0.67%
 
ACLX Arcellx, Inc.
50.65
-4.11%
 
CGON CG Oncology, Inc.
34.98
-2.98%
 
SWTX SpringWorks Therapeutics, Inc.
44.30
+2.11%
 
DYN Dyne Therapeutics, Inc.
23.85
-4.52%
 
XENE Xenon Pharmaceuticals Inc.
39.93
+1.09%
 
IDYA IDEAYA Biosciences, Inc.
38.00
-4.64%
 
MLTX MoonLake Immunotherapeutics
42.22
-0.49%
 
EWTX Edgewise Therapeutics, Inc.
15.45
-4.13%